— Know what they know.
Not Investment Advice
Also trades as: SRT3.DE (XETRA) · $vol 27M · SRT.DE (XETRA) · $vol 1M · 0NIQ.L (LSE) · $vol 0M · SARTF (OTC) · $vol 0M · SUVPF (OTC) · $vol 0M

SSSGY OTC

Sartorius AG
1W: +0.0% 1M: +0.0% 3M: +0.0% YTD: +1.4% 1Y: +16.0% 3Y: -19.5% 5Y: -77.6%
$43.93
+0.00 (+0.00%)
 
OTC · Healthcare · Medical - Instruments & Supplies · Tech Score Sell · Power 50 · $15.2B mcap · 27M float · 0.0002% daily turnover · Short 81% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$15.2B
52W Range37.87-50.95
Volume1,300
Avg Volume45
Beta1.46
Dividend$0.17
Analyst Ratings
No analyst coverage
Company Info
CEOMichael Grosse
Employees14,042
SectorHealthcare
IndustryMedical - Instruments & Supplies
IPO Date2021-01-19
Otto-Brenner-Strasse 20
Göttingen, NI 37079
DE
49 551 308 0
About Sartorius AG

Sartorius AG is an international company that provides sophisticated solutions for bioprocessing and a wide range of laboratory products and associated services. Its comprehensive product catalog features biosensor technologies, including specific kits, compliance tools, system software, label-free detection systems, and Surface Plasmon Resonance (SPR) equipment. The company also supplies advanced live-cell analysis systems, flow cytometry platforms, and various reagents and consumables for cell analysis. In the realm of media and reagents, Sartorius produces specialized formulations for antibody and recombinant protein development, viral vaccine production, regenerative medicine, and stem cell research, alongside general-purpose media, downstream buffers, and microcarriers. Additionally, it offers essential laboratory chemicals such as strong acids, bases, alcohols, and detergents. For bioreactor applications, Sartorius delivers a diverse selection, including multi-parallel, benchtop, single-use, and traditional stainless steel models designed for both cell culture and microbial processes, all supported by dedicated software applications. Its extensive filtration portfolio encompasses membranes, blotting products, various filter papers (including glass and quartz microfibre), and general filtration apparatus. This extends to syringe filters and a broad array of specialized filtration and separation devices tailored for ultrafiltration, sterile filtration, harvesting, analytical sample preparation, buffer exchange, diagnostic sample preparation, particle analysis, pharmaceutical processes, protein and DNA concentration, venting moisture barriers, and clarification. The company also provides complementary buffer and media products, along with membrane chromatography solutions. Further offerings include process filtration and chromatography solutions, fluid management systems, process analytical technology (PAT) with integrated data analytics, industrial microbiology systems, water purification units, precision weighing instruments, pipetting and dispensing systems, OEM components, and centrifuges. Beyond products, Sartorius offers a suite of services, including bioprocess development and engineering, protein expression system optimization, media and process optimization, comprehensive testing, instrument support, and validation services. The company serves a diverse client base across life science research, biopharmaceutical manufacturing, quality control and testing, and various applied industrial sectors. Founded in 1870, Sartorius AG's corporate headquarters are located in Göttingen, Germany.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms